Jazz Pharmaceuticals PLC Earnings

The next earnings date for Jazz Pharmaceuticals PLC is November 5, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Jazz Pharmaceuticals PLC Earnings

Report Date	Estimated Earnings Per Share
11/05/2025	$5.96

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Jazz Pharmaceuticals PLC Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/05/2025	---	$-8.25	-8.27%
05/07/2025	---	$1.68	-63.93%
02/25/2025	After Market	$6.60	13.58%
11/06/2024	After Market	$6.61	20.18%
07/31/2024	After Market	$5.30	11.11%
05/01/2024	After Market	$2.68	-35.89%
02/28/2024	After Market	$5.02	-3.09%
11/08/2023	After Market	$4.84	-1.83%
08/09/2023	After Market	$4.51	1.81%
05/10/2023	After Market	$3.95	-6.84%
03/01/2023	After Market	$-0.07	-121.88%
11/09/2022	After Market	$5.17	10.94%
08/03/2022	After Market	$4.30	2.63%
05/04/2022	After Market	$3.73	-2.86%
03/01/2022	After Market	$4.21	15.66%
11/09/2021	After Market	$4.20	26.51%
08/03/2021	After Market	$3.90	13.70%
05/04/2021	After Market	$3.92	5.66%
02/23/2021	After Market	$4	-4.76%
11/02/2020	After Market	$4.31	5.64%
08/04/2020	After Market	$3.71	19.29%
05/05/2020	After Market	$0.45	-32.84%
02/25/2020	After Market	$4.42	7.28%
11/05/2019	After Market	$4.10	13.89%
08/06/2019	After Market	$4.05	13.45%
05/07/2019	After Market	$3.67	16.14%
02/26/2019	After Market	$3.64	20.53%
11/06/2018	After Market	$3.58	7.83%
08/07/2018	After Market	$3.49	8.05%
05/08/2018	After Market	$2.98	7.19%
02/27/2018	After Market	$2.95	-1.01%
11/07/2017	After Market	$3.22	11.42%
08/08/2017	After Market	$2.56	-6.91%
05/09/2017	After Market	$2.31	-1.28%
02/28/2017	After Market	$2.71	2.26%
11/08/2016	After Market	$2.57	-1.53%
08/09/2016	After Market	$2.63	-6.07%
05/10/2016	After Market	$2.26	-2.16%
02/23/2016	After Market	$2.60	0.00%
11/09/2015	After Market	$2.52	-1.56%
08/05/2015	After Market	$2.41	0.00%
05/07/2015	After Market	$1.99	-7.44%
02/24/2015	After Market	$2.44	6.09%
11/04/2014	After Market	$2.33	4.96%
08/05/2014	---	$2.05	6.77%
05/08/2014	---	$1.61	-10.06%
02/25/2014	---	$1.72	-3.37%
11/05/2013	---	$1.78	6.59%
08/06/2013	---	$1.43	-5.92%
05/07/2013	---	$1.37	1.48%
02/26/2013	---	$1.53	7.75%
11/08/2012	---	$1.29	-2.27%
08/07/2012	---	$1.09	3.81%
05/08/2012	---	$0.91	8.33%
02/27/2012	---	$1.17	7.34%
11/01/2011	---	$0.94	0.00%
07/28/2011	---	$0.82	3.80%
05/03/2011	---	$0.59	3.51%
03/07/2011	---	$0.63	5.00%
11/04/2010	---	$0.41	20.59%
08/10/2010	---	$0.28	100.00%
05/05/2010	---	$0.18	0.00%
03/03/2010	---	$0.17	142.86%
11/05/2009	---	$-0.05	64.29%
08/11/2009	---	$0.07	121.88%
05/07/2009	---	$-0.45	---
03/26/2009	---	$-2.04	-90.65%
11/13/2008	---	$-1.07	17.05%
08/07/2008	---	$-2.17	-21.91%
05/13/2008	---	$-1.97	-25.48%
02/13/2008	---	$-1.69	7.14%
11/06/2007	---	$-0.82	41.43%
08/09/2007	---	$-1.38	18.34%

More About Jazz Pharmaceuticals PLC

Website

https://www.jazzpharma.com

Country

USA

Full Time Employees

2,800

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

“Jazz Pharmaceuticals PLC Earnings” Can Refer to the Jazz Pharmaceuticals PLC Earnings Date

Some people say “Jazz Pharmaceuticals PLC earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Jazz Pharmaceuticals PLC position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Jazz Pharmaceuticals PLC Stock on the Earnings Date

If you own Jazz Pharmaceuticals PLC stock (JAZZ) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Jazz Pharmaceuticals PLC might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Jazz Pharmaceuticals PLC shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Jazz Pharmaceuticals PLC Earnings

You can contact us any time if you would like to ask questions about Jazz Pharmaceuticals PLC earnings or anything else related to the stock market.